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ABSTRACT: Objective—To compare the effects of a low-dose oral contraceptive containing desogestrel (Mar- 
velon) and an anti-androgenic preparation containing cyproterone acetate (Diane) in Oriental women suffer­
ing from acne. Methods—In an open-label, bi~center, randomized study, 32 women using Marvelon® and 34 
using Diane® were followed for 6 treatment cycles. The measured variables were objective and subjective 
severity of acne, and related biochemical variables such as sex hormone-binding globulin and free and total 
testosterone. Results—In Center A, with both preparations a decrease in mean objective acne score was 
observed, reaching statistical significance with Diane (P < .05). In addition, there was a significant between- 
group difference at cycle 6 (P < .05). In Center B, a consistent and significant decrease in mean acne score 
was observed with Marvelon after three and six treatment cycles [P < .05 and P < .01) and with Diane after 
six treatment cycles [P < .001). There were no significant between-group differences. The decrease in per­
centage of severe/moderate acne was statistically significant with Marvelon in Center B [P = 0.002) and with 
Diane in Centers A [P = 0.014) and B [P = 0.004). Both preparations increased plasma levels of sex hormone 
binding globulin and seemed to decrease those of total and free testosterone, but no statistically significant 
relationships between acne severity and biochemical variables could be detected. Conclusion—Both Mar­
velon and Diane are effective in the treatment of acne in Oriental women who also need reliable contracep­
tion, without marked differences between the preparations. Int J Pertil 41(4):423-429, 1996
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INTRODUCTION
■■ CNE VULGARIS IN WOMEN USUALLY
starts to develop with adrenarche, and its 
severity usually declines after puberty. It 
J f ^ ^ h a s  been reported that up to 30% of 
teenagers develop acne of sufficient severity to 
require medical treatment. Androgens increase 
sebaceous gland size and sebum production, 
whereas estrogens decrease sebum production by 
suppressing pituitary gonadotropin secretion as well 
as ovarian and adrenal androgen secretion. Estro­
gens also increase hepatic synthesis of sex hor­
mone-binding globulin (SHBG), resulting in 
increased SHBG plasma levels. In contrast, andro­
gens, as well as progestogens with intrinsic andro­
genic activity, reduce SHBG plasma concentrations. 
SHBG plays an important role in binding circulat­
ing androgens, thereby decreasing free androgen 
concentrations [1].
Combined oral contraceptives (OCs) have been 
implicated in both the pathogenesis and treatment 
of acne: estrogen-dominant preparations may 
induce improvement of preexisting acne [2-5], 
whereas androgen-dominant OCs, particularly 
those containing 1-norgestrel, have been reported to 
be associated with exacerbation of acne and even 
with triggering the development of acne [4-7].
Desogestrel, a gonane progestogen with low 
intrinsic androgenic activity, and cyproterone 
acetate, an anti-androgen from the pregnane group, 
with weak progestogenic activity, are both used as 
the progestogenic component in combined OCs. 
Cyproterone acetate-containing preparations are 
also used in various countries for treatment of 
androgenic (skin) disorders. Because of the absence 
of androgenic effects with desogestrel- and cypro­
terone acetate-based OCs, they are both suitable 
for use by women who suffer from acne and/or 
hirsutism and who also need reliable, reversible 
contraception.
The clinical efficacy of both preparations, 
whether used in OCs or in the treatment of acne, is 
well established with regard to women in Western 
countries. However, how these preparations would 
perform as anti-acne treatment for Asian women is 
largely unknown. In addition, it is not clear 
whether the changes in acne severity with use of 
OCs are correlated with the changes in biochemi­
cal variables, such as SHBG and total and free 
testosterone (T). The main objective of our study
was to compare the efficacy in acne treatment of 
Oriental women of an OC preparation containing 
desogestrel and an anti-androgenic preparation con­
taining cyproterone acetate.
METHODS 
Design
This randomized, bi-center, open-label, compara­
tive study with a duration of 6 treatment cycles 
was performed in two centers in Thailand: the 
Prince of Sonkhla University in Sonkhla (Center A; 
17 women on desogestrel and 19 on cyproterone 
acetate) and the Rajvithi Hospital in Bangkok (Cen­
ter B, 15 women on desogestrel and 15 women on 
cyproterone acetate). Before entering the study all 
subjects had given voluntary, informed consent. 
The study was conducted in compliance with both 
the Declaration of Helsinki and local rules and reg­
ulations, as well as local ethical standards.
Selection of Subjects
Subjects eligible for inclusion were women who 
had a wish to use OCs, presenting with acne, 
between 16 and 30 years of age, and willing to give 
their informed consent. Exclusion criteria were 
contraindications to the use of OCs, current use of 
systemic treatment for acne, delivery or abortion 
within the last 6 months, breastfeeding within the 
last 3 months, treatment with other OCs or treat­
ment with injectable contraceptives in the last 3 
months. Subjects were withdrawn from the study if 
contraindications to OCs use developed, or if dis­
ease occurred making further participation in the 
study impossible or unethical.
Study Drugs and Dosage instructions
Eligible subjects were randomized to one of the fol­
lowing two study medications: (1) 150 jag deso­
gestrel plus 30 jig ethinyl estradiol (Marvelon®, 
N.V. Organon, Oss, the Netherlands) for oral 
administration; (2) 2,000 jig cyproterone acetate 
plus 50 jig ethinyl estradiol (Diane®, Schering AG, 
Berlin, Germany) for oral administration.
The study consisted of a baseline cycle in which 
no study medication was taken, and six successive 
treatment cycles. Dosage instructions were similar
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for both study medications: following the baseline 
cycle, the first tablet was taken on the first day of 
menstruation. Tablets were to be taken for 21 con­
secutive days, followed by a 7-day tablet-free inter­
val. The same dosage schedule was used in the 
subsequent five treatment cycles.
Procedures and Evaluation Methods
After enrollment into the study, during the base­
line cycle the subjects were checked for inclusion 
and exclusion criteria and medical history was 
taken; a medical examination, including measure­
ment of blood pressure, and a gynecological inves­
tigation were performed. During this baseline cycle 
the severity of acne was rated. The acne rating in 
both centers was performed semi-quantitatively by 
counting the number of facial comedones, papules, 
and pustules. In addition, in Center A the number 
of nodulocystic lesions was also recorded. Acne 
severity was rated as follows:
absent (acne score = 0): no acne at all
mild (acne score = 1):
moderate 
acne score « 2):
<15 comedones + <10 
papules + <5 pustules
>15 comedones or 
10 papules or 
>5 pustules and 
<5 nodulocystic lesions 
severe (acne score = 3): £5 nodulocystic lesions
In addition to this semi-quantitative method of 
acne rating, a subjective impression of acne sever­
ity by the patients themselves was also recorded 
during each visit. However, the two study centers 
employed different methodologies for the subjec­
tive assessment of acne. In Center A, patients were 
asked about the possible change from baseline in 
the severity of acne. The possible answers from 
which to choose were "cured", "improved," "no 
change," and 
patients were asked how they regarded their acne 
severity at the time of the visit. The possible 
answers here were "absent," "mild," "moderate,"
for analysis at the biochemical research and devel­
opment laboratories of N.V. Organon in Oss, the 
Netherlands. Laboratory variables were assessed by 
previously published methods [8].
Subsequent clinic visits were scheduled after 
one, three and six treatment cycles. During each of 
these visits, the severity of acne was rated both 
objectively and subjectively and a medical exami­
nation was performed. During cycles 3 and 6 blood 
samples were drawn for the assessment of bio­
chemical variables.
Statistical Analysis
For each of the treatments the changes in semi- 
quantitative acne score over time were analyzed by 
the Wilcoxon test for paired observations. These 
changes were also compared between both groups 
by means of a Wilcoxon two-sample test. To inves­
tigate trends in the percentage of patients with 
moderate/severe acne over time, the chi-square 
trend test of van Eeden and Hemelrijk [9] was used. 
A logistic regression analysis was done to investi­
gate the relationship between the severity of acne 
(percentage moderate/severe) and the blood values 
at baseline. The changes in blood values after 3 and 
6 months were compared with the change in acne 
score (equal or decreased) after 3 and 6 months 
using Student's t test.
Because the number of nodulocystic lesions was 
not systematically recorded in Center B, an acne 
score of 3 (severe) could usually not be checked. In 
view of these fundamental between-center differ­
ences in scales for rating the severity of acne, it 
was decided to perform separate statistical analyses 
for each of the centers.
RESULTS
"worse." In Center B, though, the
Subject Characteristics
Analysis of the demographic characteristics of the 
study groups revealed that they were comparable 
with respect to mean age, age at menarche, parity, 
body weight and blood pressure. At baseline no sta­
tistically significant differences were observed 
In addition to semi-quantitative and subjective between preparations or between centers. Although 
acne rating, blood was drawn for assessment of bio- 11 subjects were over 30 years of age (the niaxi- 
chemical variables (SHBG, free T, total T). After mum age according to the protocol), it was decided 
blood collection, the samples were stored at -20°C not to exclude them from the analyses.
and "severe."
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Effects on Acne
The semi-quantitative mean acne scores with Mar- 
velon and Diane at baseline and after one, three, 
and six treatment cycles are presented for both cen­
ters in Figures 1 and 2.
In Center A, with Marvelon the decrease in 
mean semi-quantitative acne score did not reach 
statistical significance, whereas with Diane the 
decrease reached statistical significance after 3 and 
6 treatment cycles [P < .05). In addition, there was 
a statistically significant difference in the change 
in acne scores between both groups at cycle 6 [P < 
.05). In Center B with both preparations a consis­
tent decrease in mean acne score could be 
observed, and was statistically significant with 
Marvelon after 3 and 6 treatment cycles [P < .05 
and P < .01, respectively), and with Diane after 6 
treatment cycles (P < .001). There were no signifi­
cant between-group differences in Center B.
PIG. 1. Mean acne score in Center A. *P < .05 vs. base­
line; #P < .05, Marvelon vs. Diane.
FIG. 2. Mean acne score in Center B. *P < .05, **P < .01, 
***P < .001 vs. baseline.
The change in the percentage of patients with 
moderate/severe acne score per treatment group and 
per center was tested with the trend test of van 
Eeden and Hemelrijk [9]. In Center A, the percent­
ages of subjects with moderate/severe acne at base­
line and during cycles 1, 3, and 6 with Marvelon 
were 53%, 50%, 36%, and 43%, which did not 
reach statistical significance for trend (P « 0.64), 
whereas with Diane the corresponding percentages 
were 63%, 44%, 18%, and 12%, a change statisti­
cally significant for trend (P » 0.014). In Center B, 
the percentages of subjects with moderate/severe 
acne for Marvelon were 100%, 93%, 50%, and 
0%—statistically significant for trend (P « 0.002); 
for Diane these percentages were 100%, 80%, 50%, 
and 7%, also statistically significant for trend (P =
0.004). There were no statistically significant trend 
differences between the two preparations in either 
center.
After six treatment cycles the objective acne 
scores had decreased in about 50% of subjects in 
Center A and in almost all subjects in Center B 
(data not shown). There was no statistically signifi­
cant difference in the percentage of patients with a 
decrease in acne score between the two treatment 
groups (chi-square-test, Center A: P = 0.89; Center
B: P = 0.37).
The subjective acne scores in this study were in 
line with the semi-quantitative measurements as 
presented earlier, since the patient's opinion con­
cerning the effect on acne usually followed the 
changes that were reported after objective judge­
ment. In Center A, of the 14 subjects in the Mar­
velon group who completed the study, 13 had 
noted a subjective improvement, whereas one sub­
ject felt that there had been no change in her acne 
status. Of the 17 who completed the study in the 
Diane group, 14 considered the acne either cured 
(1) or improved (13), whereas the remaining three 
subjects reported no change from baseline. In Cen­
ter B, a similar observation was made: at baseline 
all 15 subjects in the Marvelon group considered 
their acne as being either moderate (9) or severe 
(6), whereas after six treatment cycles all 12 
remaining subjects considered their acne as absent 
(10) or mild (2). In the Diane group the same 
trend was observed: at baseline all 15 subjects con­
sidered their acne as moderate, (6) or severe (9), 
whereas at the end of the study all 14 remaining 
subjects considered their acne as being either 
absent (9) or mild (5).
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TABLE I
Effects on biochemical variables with Marvelon® and Diane® per cycle (mean ± SE)
Variable
SHBG (nmol/L) 
Marvelon 
Diane
Baseline
95.0 ± 14.8 
83.2 ±8.1
Center A
Cycle 3
159.0 ± 13.44=
181.2 ± 14.2*
Cycle 6
155.0 ± 15.8+ 
175.3 ± 16.1+
Baseline
51.1 ± 7.5 
65.5 ±7.1
Center B
Cycle 3
144.8 ±22.2+
203.8 ±24.0+
Cycle 6
142.2 ± 12,5+
188.2 ±33.9+
Total T (nmol/L) 
Marvelon 
Diane
2.33 ± 0.44 
2.21 ± 0.32
1.67 ±0.44* 
1.35 ± 0.29+
1.60 ± 0.44* 
2.18 ± 0.44
2.47 ± 0.26 
2.37 ± 0.27
1.49 ±0.23+ 
1.76 ± 0.27*
1.67 ±0.28+ 
1.88 ±0.29
Free T (pmol/L) 
Marvelon 
Diane
10.51 ± 1.83 
8.72 ± 0.95
5.98 ±1.02+ 
5.29 ±0.80+
6.48 ± 1.08* 
7.52 ± 1.11
4.07 ± 0.70 
3.05 ± 0.33
2.24 ± 0.43+ 
2.04 ± 0.32+
2.41 ± 0.48+ 
2.40 ± 0.24
P < .05, +P < .01, +P < .001 vs. baseline. T = testosterone.
Effects on Biochemical Variables
The effects of the two treatments on plasma levels 
of SHBG, total T, and free T are presented in Table
I. After three and six treatment cycles, in both 
study centers Marvelon and Diane induced a statis­
tically significant increase in SHBG plasma levels 
(P < .01). Although there was a decrease in plasma 
levels of both total and free T with both prepara­
tions, after six cycles the changes only reached sta­
tistical significance with Marvelon [P < 0.05). 
There were no statistically significant differences 
between the preparations, and there were no corre­
lations between the changes in acne score and the 
changes in biochemical variables (data not shown).
Drop-outs
Of the 66 enrolled subjects, six in the Marvelon and 
three in the Diane group did not complete the study. 
The reasons for drop-out in the Marvelon group 
were: severe headache/dizziness (1), weight gain (1), 
loss to follow-up (2), and migration (2). In the Diane 
group, subjects dropped out because of severe 
headache/dizziness (1), and unknown reasons (2).
DISCUSSION
In this study, both Marvelon and Diane were effec­
tive in treatment of acne, without marked differ­
ences between the preparations. One of the causes 
for a between-group difference in mean acne score 
at cycle 6 in Center A might well be chance, since 
the difference only reached borderline significance 
(P = 0.038), whereas all other differences in Centers 
A and B between Marvelon and Diane were not sta­
tistically significant. The small groups at each 
treatment center as well as the between-center dif­
ferences in acne rating methodology may have 
played a role here.
During use of Marvelon or Diane, plasma con­
centrations, of SHBG usually increase by about 
200%, since this, estrogen-dependent effect is not 
counteracted by the intrinsic androgenicity of the 
progestogenic component in these OCs. The 
increase of SHBG results in an increased protein 
binding of plasma T, thereby reducing the free 
plasma T concentration. It is thought that the 
plasma concentrations of free (and therefore active) 
T are correlated with the severity of acne [10]/The 
decrease in free plasma T concentration as 
observed in most studies with Marvelon and Diane 
may therefore influence acne symptoms favorably 
[8,11], although in this study no correlation 
between changes in severity of acne and changes in 
biochemical variables could be found.
In two Phase IV studies with 11,605 [12] and 
1,958 [13] subjects, the use of Marvelon has been 
shown to improve subjectively rated pre-existing 
acne in 42-75% of women after six cycles of use,
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depending on the severity of symptoms (improve­
ment seemed to be better with m ild and moderate 
acne than with severe acne). In another open study 
in hyperandrogenic adolescents with moderate or 
severe facial and body acne, Marvelon induced an 
improvement in acne symptoms in all subjects dur­
ing treatment, with a complete disappearance of 
symptoms in 90% of the subjects after 1 year of 
treatment [14]. It must be noted here, however, 
that the study by Bilotta and Favilli [12] was not 
especially designed to demonstrate efficacy on 
acne, and valid conclusions should preferably be 
drawn from well-controlled studies specially 
designed to investigate the effect of OCs on acne.
In a 6-cycle controlled study investigating the 
effect of OCs on acne, Marvelon increased SHBG 
and decreased free T plasma concentrations, with a 
statistically significant improvement of acne symp­
toms when compared with pretreatment. In addi­
tion, this improvement was statistica lly  
significantly better than with a levonorgestrel-con- 
taining OC [15], as measured by the modified photo­
graphic acne rating method of Allen and Smith [16].
Like Marvelon, Diane has been demonstrated to 
be effective in treatment of acne, both in compari­
son with baseline [17-19] and also with OCs con­
taining levonorgestrel [17]. In a previous direct 
comparative study in France, Marvelon and Diane 
were equally effective in the treatment of m ild to 
moderate acne [20]. This result is in line with the 
results of the present study.
Although it has been suggested that the anti­
acne efficacy of Diane can be attributed to the anti- 
androgenic properties of cyproterone acetate, this is 
questioned by others: the contraceptive cypro­
terone acetate dose of 2 mg in  Diane would be 
much too low to exert a clinically detectable effect. 
The absence of an important role of the cypro­
terone acetate dose in acne efficacy is supported by 
a study in which it was demonstrated that after 6 
months of treatment there was no statistically sig­
nificant difference in mean acne score between two 
preparations each containing 50 ]xg of ethinyl estra­
diol, but greatly different doses of cyproterone 
acetate (2 mg and 50 mg) [21]. Consequently, the 
anti-acne effect of D iane should probably be 
attributed mainly to the ethinyl estradiol compo­
nent in the preparation [22]. In this respect, the 
results of the current study are remarkable, since 
the efficacy on acne was more or less similar with 
both study preparations, despite the lower daily
dose of ethinyl estradiol of 30 jag w ith Marvelon as 
compared to 50 pg w ith Diane.
The results of the present study on Oriental 
women are largely comparable to those obtained 
earlier on Caucasian women. Use of either Mar­
velon or Diane resulted in significant objective and 
subjective improvement of acne symptoms in the 
majority of Oriental women. In general, no marked 
between-group differences were detected.
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